Catalyst
Slingshot members are tracking this event:
PharmaMar (PHM.MC) Completes Enrollment for Phase 3 CORAIL Trial Evaluating PM1183 (lurbinectedin) in Platinum-Resistant Ovarian Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PHM.MC |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 18, 2016
Related Projects
- A conversation with PharmaMar's Director of Oncology, Newly Hired COO, and Director of Capital Markets to discuss the upcoming pivotal year for the firm. PHM.MC, CLVS, TSRO Executed On: Mar 09, 2017 at 11:00 AM EST
Related Keywords
Enrollment, Phase 3, Corail, Pm1183, Lurbinectedin, Platinum Resistant Ovarian Cancer
